Overview
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This will be achieved through the measurement of donor-derived cell-free DNA. The utility of donor-derived cell-free DNA will be validated based on histological findings using Receiver Operating Characteristics (ROC) curve analysis.
Eligibility
Inclusion Criteria:
- Recipients aged 18 and above
- Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than 1000. Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months.
- Patients with detected de novo HLA-DSAs but did not undergo histological examinations.
Exclusion Criteria:
- Multi-organ transplant recipients
- Recipients with positive preformed DSAs
- ABO-incompatible transplant recipients
- Pediatric recipients under 18 years old at the time of transplantation
- Recipients lost to follow-up observation
- atients already subjected to histological examinations due to positive De novo HLA-DSAs.